Martin Treder

952 total citations
33 papers, 642 citations indexed

About

Martin Treder is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Martin Treder has authored 33 papers receiving a total of 642 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 21 papers in Radiology, Nuclear Medicine and Imaging and 16 papers in Immunology. Recurrent topics in Martin Treder's work include Monoclonal and Polyclonal Antibodies Research (21 papers), CAR-T cell therapy research (14 papers) and Immune Cell Function and Interaction (13 papers). Martin Treder is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (21 papers), CAR-T cell therapy research (14 papers) and Immune Cell Function and Interaction (13 papers). Martin Treder collaborates with scholars based in Germany, United States and China. Martin Treder's co-authors include Uwe Reusch, Axel Ullrich, Joachim Koch, Erich Rajkovic, Axel Choidas, Thorsten Gantke, Karl Drlica, Anil Koul, Akhilesh K. Tyagi and Yogendra Singh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Martin Treder

30 papers receiving 618 citations

Peers

Martin Treder

ONCOL

IMMUN

RNMI

HEMAT

Rajesh Vij United States

Wim J.E. van Esch Netherlands

Koen Wagner Netherlands

Marcia Stickler United States

Rami Yossef Israel

Geir Åge Løset Norway

Govind Panchamoorthy United States

Armelle Goubard France

Gabriele Pecher Germany

Daniel J. Kowalewski Germany

Rajesh Vij United States

Martin Treder

265 ×0.8

ONCOL

104 ×0.4

IMMUN

365 ×1.5

140 ×0.7

RNMI

51 ×0.7

HEMAT

Citations per year, relative to Martin Treder Martin Treder (= 1×) peers Rajesh Vij

Countries citing papers authored by Martin Treder

Since Specialization

Citations

This map shows the geographic impact of Martin Treder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Treder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Treder more than expected).

Fields of papers citing papers by Martin Treder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Treder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Treder. The network helps show where Martin Treder may publish in the future.

Co-authorship network of co-authors of Martin Treder

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Treder. A scholar is included among the top collaborators of Martin Treder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Treder. Martin Treder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hacker, Lina, Anthony J. Chalmers, Ross Breckenridge, et al.. (2024). The activity of therapeutic molecular cluster Ag5 is dependent on oxygen level and HIF-1 mediated signalling. Redox Biology. 76. 103326–103326. 4 indexed citations

Treder, Martin. (2023). Wie viel CO2 entsteht bei der Abfallverbrennung?. 42(1). 22–29.

Marín, Nancy D., Michelle Becker‐Hapak, Joachim Koch, et al.. (2019). Abstract 1546: The CD30/CD16A bispecific innate immune cell engager AFM13 elicits heterogeneous single-cell NK cell responses and effectively triggers memory-like (ML) NK cells. Cancer Research. 79(13_Supplement). 1546–1546. 1 indexed citations

Pahl, Jens, Joachim Koch, Annette Arnold, et al.. (2018). CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells. Cancer Immunology Research. 6(5). 517–527. 104 indexed citations

Wingert, Susanne, Uwe Reusch, Jens Pahl, et al.. (2018). CD16A-Specific Tetravalent Bispecific Immune Cell Engagers Potently Induce Antibody-Dependent Cellular Phagocytosis (ADCP) on Macrophages. Blood. 132(Supplement 1). 1111–1111. 2 indexed citations

Gantke, Thorsten, Uwe Reusch, Christian Kellner, et al.. (2017). AFM26 - Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma. Blood. 130. 3082–3082. 6 indexed citations

Ellwanger, Kristina, Uwe Reusch, Ivica Fucek, et al.. (2017). Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies. Frontiers in Oncology. 7. 100–100. 25 indexed citations

Gantke, Thorsten, Michael Weichel, Uwe Reusch, et al.. (2017). Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells. Protein Engineering Design and Selection. 30(9). 673–684. 46 indexed citations

Kerber, A., Michael Kluge, Uwe Reusch, et al.. (2017). EGFR/CD16A tetravalent bispecific antibody AFM24 to engage NK-cells to kill EGFR expressing tumor cells and safety results in cynomolgus monkey studies.. Journal of Clinical Oncology. 35(15_suppl). e14001–e14001. 3 indexed citations

10.

Gantke, Thorsten, Uwe Reusch, Kristina Ellwanger, et al.. (2017). Abstract 5671: AFM26 - A novel CD16A-directed bispecific TandAb targeting BCMA for multiple myeloma. Cancer Research. 77(13_Supplement). 5671–5671. 4 indexed citations

11.

Weinschenk, Toni, Erich Rajkovic, Uwe Reusch, et al.. (2017). Abstract 3753: Identification of antibodies against a novel tumor-associated MHC/peptide-target and generation of highly specific and potent HLA-A*02MMP1-003/CD3 TandAbs. Cancer Research. 77(13_Supplement). 3753–3753. 1 indexed citations

12.

Pahl, Jens, Uwe Reusch, Thorsten Gantke, et al.. (2016). AFM13 Is the Most Advanced Bispecific NK-Cell Engaging Antibody in Clinical Development Substantially Enhancing NK-Cell Effector Function and Proliferation. Blood. 128(22). 1764–1764. 2 indexed citations

13.

Zhao, Xing, et al.. (2015). CD137 co-stimulation and blocking PD-1 enhances NK cell-mediated target cell lysis by CD30/CD16A TandAb AFM13.. Journal of Clinical Oncology. 33(15_suppl). 3050–3050. 1 indexed citations

14.

Zhao, Xing, Narendiran Rajasekaran, Uwe Reusch, et al.. (2015). In Vitro and In Vivo Characterization of CD19/CD3 Tandab AFM11 and CD19/CD16A Tandab AFM12 Targeting NHL. Blood. 126(23). 2763–2763. 1 indexed citations

15.

Gupta, Anurag, Natko Nuber, Christoph Esslinger, et al.. (2013). A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. PubMed. 13. 3–3. 17 indexed citations

16.

Freeman, Daniel J., et al.. (2008). Fully human Anti-HER3 monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor activities versus other HER family inhibitors. Cancer Research. 68. 19 indexed citations

17.

Treder, Martin, Susanne Hartmann, Eric Borges, et al.. (2008). Fully human Anti-HER3 monoclonal antibodies (mAbs) inhibit oncogenic signaling and tumor cell growth in vitro and in vivo. 68. 14 indexed citations

18.

Treder, Martin, et al.. (2008). 309 POSTER Fully human anti-HER3 mAb U3-1287 (AMG 888) demonstrates unique in vitro and in vivo activities versus other HER family inhibitors in NSCLC models. European Journal of Cancer Supplements. 6(12). 99–99. 15 indexed citations

19.

Horst, Edward H. van der, Marta Murgia, Martin Treder, & Axel Ullrich. (2005). Anti‐HER‐3 MAbs inhibit HER‐3‐mediated signaling in breast cancer cell lines resistant to anti‐HER‐2 antibodies. International Journal of Cancer. 115(4). 519–527. 45 indexed citations

20.

Koul, Anil, Axel Choidas, Martin Treder, et al.. (2000). Cloning and Characterization of Secretory Tyrosine Phosphatases of Mycobacterium tuberculosis. Journal of Bacteriology. 182(19). 5425–5432. 156 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact